Clinical Features Associated with COVID-19 Outcome in MM: First Results from International Myeloma Society Dataset

TY - JOUR

T1 - Clinical Features Associated with COVID-19 Outcome in MM: First Results from International Myeloma Society Dataset

AU - Chari, Ajai

AU - Samur, Mehmet Kemal

AU - Martinez-Lopez, Joaquin

AU - Cook, Gordon

AU - Biran, Noa

AU - Yong, Kwee L

AU - Hungria, Vania Tietsche de Moraes

AU - Engelhardt, Monika

AU - Gay, Francesca

AU - Garcia-Feria, Ana

AU - Oliva, Stefania

AU - Oostvogels, Rimke

AU - Gozzetti, Alessandro

AU - Rosenbaum, Cara A

AU - Kumar, Shaji K

AU - Stadtmauer, Edward

AU - Einsele, Hermann

AU - Beksac, Meral

AU - Weisel, Katja C

AU - Anderson, Kenneth C

AU - Mateos, Maria-Victoria

AU - Moreau, Philippe

AU - San Miguel, Jesús

AU - Munshi, Nikhil C

AU - Avet-Loiseau, Hervé

N1 - Copyright © 2020 American Society of Hematology.

PY - 2020/11/6

Y1 - 2020/11/6

N2 - The primary cause of morbidity and mortality in patients with multiple myeloma(MM) is an infection. Therefore there is great concern about the susceptibility to the outcome of COVID-19 infected patients with MM. This retrospective study describes the baseline characteristics and outcome data of COVID-19 infection in 650 patients with plasma cell disorders, collected by the International Myeloma Society to understand the initial challenges faced by myeloma patients during COVID-19 pandemic. Analysis were performed for hospitalized MM patients. Among hospitalized patinets, the median age was 69 years, and nearly all patients(96%) had MM. Approximately 36% were recently diagnosed(2019-2020), and 54% of patients were receiving first-line therapy. Thirty-three percent of patients have died, with significant geographic variability, ranging from 27% to 57% of hospitalized patients. Univariate analysis identified age, ISS3, high-risk disease, renal disease, suboptimal myeloma control(active or progressive disease), and one or more comorbidities as risk factors for higher rates of death. Neither history of transplant, including within a year of COVID-19 diagnosis, nor other anti-MM treatments were associated with outcomes. Multivariate analysis found that only age, high-risk MM, renal disease, and suboptimal MM control remained independent predictors of adverse outcome with COVID-19 infection. The management of MM in the era of COVID-19 requires careful consideration of patient and disease-related factors to decrease the risk of acquiring COVID-19 infection, while not compromising disease control through appropriate MM treatment. This study provides initial data to develop recommendations for the management of MM patients with COVID-19 infection.

AB - The primary cause of morbidity and mortality in patients with multiple myeloma(MM) is an infection. Therefore there is great concern about the susceptibility to the outcome of COVID-19 infected patients with MM. This retrospective study describes the baseline characteristics and outcome data of COVID-19 infection in 650 patients with plasma cell disorders, collected by the International Myeloma Society to understand the initial challenges faced by myeloma patients during COVID-19 pandemic. Analysis were performed for hospitalized MM patients. Among hospitalized patinets, the median age was 69 years, and nearly all patients(96%) had MM. Approximately 36% were recently diagnosed(2019-2020), and 54% of patients were receiving first-line therapy. Thirty-three percent of patients have died, with significant geographic variability, ranging from 27% to 57% of hospitalized patients. Univariate analysis identified age, ISS3, high-risk disease, renal disease, suboptimal myeloma control(active or progressive disease), and one or more comorbidities as risk factors for higher rates of death. Neither history of transplant, including within a year of COVID-19 diagnosis, nor other anti-MM treatments were associated with outcomes. Multivariate analysis found that only age, high-risk MM, renal disease, and suboptimal MM control remained independent predictors of adverse outcome with COVID-19 infection. The management of MM in the era of COVID-19 requires careful consideration of patient and disease-related factors to decrease the risk of acquiring COVID-19 infection, while not compromising disease control through appropriate MM treatment. This study provides initial data to develop recommendations for the management of MM patients with COVID-19 infection.

U2 - 10.1182/blood.2020008150

DO - 10.1182/blood.2020008150

M3 - SCORING: Journal article

C2 - 33156904

JO - BLOOD

JF - BLOOD

SN - 0006-4971

ER -